Bortezomib accord 3.5 mg/1.4 ml RTU
Description: Bortezomib Accord is a “generic medicine” containing the same active substance as the reference medicine, Velcade. It is an antineoplastic (cancer) medicine in a class called proteasome inhibitors. The product is a clear, colorless solution for injection, provided in glass vials.
Share Now
Additional Information
Product Name Bortezomib Accord 2.5 mg/mL solution
Active Ingredient: Bortezomib
Description: Bortezomib Accord is a “generic medicine” containing the same active substance as the reference medicine, Velcade. It is an antineoplastic (cancer) medicine in a class called proteasome inhibitors. The product is a clear, colorless solution for injection, provided in glass vials.
Indication It is used to treat adults with two types of blood cancer:
- Multiple Myeloma: Used alone or in combination with other drugs (like dexamethasone or melphalan) for patients whose disease is worsening after prior treatment, or for previously untreated patients who may or may not be eligible for blood stem-cell transplantation.
- Mantle Cell Lymphoma: Used in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone for previously untreated adults who cannot have blood stem-cell transplantation.
Strength 2.5 mg/mL (available in 1 mL vials containing 2.5 mg or 1.4 mL vials containing 3.5 mg of bortezomib).
Business Partner Accord Healthcare
Related Products
Related products
Disclaimer
Pharma Solutions is the master distributor for the listed products in Egypt. The products are either registered and approved by the respective local health authority or contracted by the MAH to supply to the end users on a named patient basis. Some products such as Orphan drugs, rare diseases medicines are imported based on special import permits and as per need of the Hospitals in compliance with full documentation.